Swapping meat for Quorn lowers bad cholesterol by 10-percent

Regularly substituting meat for mycoprotein such as Quorn could help to lower bad cholesterol by 10-percent, which is comparable to switching to a Mediterranean or vegan diet.

New research by the University of Exeter, published in Clinical Nutrition, also found substituting meat for Quorn reduces blood glucose and c-peptide concentrations associated with diabetes, cardiovascular disease and all-cause mortality.

With one in six UK adults suffering from raised cholesterol, the findings indicate that mycoprotein – the high protein, high-fibre food source that’s the main ingredient in Quorn – could play a key role in cholesterol management and improving heart health.

Dr George Pavis, of University of Exeter, led the study and said: “We’re really excited about these results and what they mean for public health. Previous laboratory studies, where all food eaten is controlled and alcohol and caffeine consumption regulated, have clearly shown that daily consumption of mycoprotein reduces bad cholesterol. But this is the first study of its kind to explore the impact of such a dietary intervention in a real-world, home-based setting where participants were not restricted in terms of what else they consumed or did.

“The findings demonstrate that introducing Quorn foods into a diet on a regular basis helps to significantly lower bad cholesterol, blood glucose and c-peptide concentrations, which is important for boosting heart health and reducing the risk of cardiovascular disease.

“It was particularly interesting to see the scale of the impact that Quorn consumption had in terms of reducing harmful cholesterol, with its performance over four weeks comparable to what we might expect to see from well-established approaches, such as following a Mediterranean diet.”

The remotely delivered study involved 72 overweight adults with high cholesterol levels. Researchers found that participants who ate 180g of Quorn products on a daily basis – equivalent to two servings of Quorn mince – saw a 10-percent reduction in ‘bad’ LDL cholesterol over the four-week study period. This equates to a 0.3 millimole per litre (mmol/l) decrease in bad cholesterol levels in less than one month.

Research has shown how more wholesale healthy dietary changes, such as switching to a Mediterranean or vegan diet, will typically deliver a 0.2 – O.3 mmol/l reduction in bad cholesterol levels after 12 weeks. Researchers at the University of Exeter also noted that typical doses of atorvastatin, the most popular statin prescribed by the NHS to treat high cholesterol, commonly yield a 0.3 – 1.3 mmol/l reduction after 12 months.

According to medical research, a decrease of 0.39 mmol/l in bad cholesterol levels is associated with a 25% lower lifetime risk of heart and circulatory disease. With pharmaceutical trials suggesting that reductions increase in a linear way over time, the researchers suggested further studies should be undertaken to see if the results improve even further when Quorn is eaten over a longer period.

The study – which saw half of the participants (39) given meat and fish products to eat on a daily basis as part of their regular diet, while the other half (33) were provided with Quorn products – also revealed further heart health benefits.

High blood sugar levels and c-peptide concentrations are commonly associated with diabetes and an increased risk of cardiovascular disease and all-cause mortality. The researchers found that study participants who ate Quorn products experienced, on average, a 13-percent drop in blood glucose levels and a 27-percent fall in c-peptide concentrations, compared with the control group. With current data showing that 2.4 million people are at an increased risk of type 2 diabetes in the UK based on high blood sugar levels, these findings demonstrate how mycoprotein could also play a key role in tackling a disease that currently costs an estimated £14 billion a year to treat.

The findings come after the latest annual Health Survey for England estimated that well over half (59-percent) of adults suffer from raised cholesterol and one in ten from diabetes, with both conditions known to cause cardiovascular disease – meaning millions of people could be at risk of a potentially fatal heart attack or stroke.

Sam Blunt, Quorn’s director of sustainability and corporate affairs, said: “The potential cholesterol-lowering effects of Quorn’s mycoprotein were first identified nearly four decades ago and, since then, numerous studies have helped us to understand more about the extent of its cholesterol management capabilities, with its high-fibre content thought to play a key role in this.

“While the benefits of adopting a Mediterranean diet are clear, it’s not always easy to do and this study highlights how, by simply introducing Quorn products into their diet on a regular basis, people may be able to quickly reduce their cholesterol levels and improve their heart health with minimal effort.”

Reference:

George F. Pavis, Raquel Revuelta Iniesta, Holly Roper, Tim J.A. Finnigan, Francis B. Stephens, Benjamin T. Wall, A four-week dietary intervention with mycoprotein-containing food products reduces serum cholesterol concentrations in community-dwelling, overweight adults: A randomised controlled trial, Clinical Nutrition, DOI:https://doi.org/10.1016/j.clnu.2024.01.023.

Powered by WPeMatico

FDA Approves Clobetasol Propionate Ophthalmic Suspension for Post-Operative Ocular Care

The FDA has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007) for managing post-operative inflammation and pain following ocular surgery. This approval marks a significant advancement in ocular care, offering a novel treatment option for patients undergoing various eye procedures.

Ocular surgery is commonly associated with inflammation and discomfort post-procedure, necessitating effective management strategies. The approval of clobetasol propionate ophthalmic suspension addresses this need by providing a potent corticosteroid formulation for alleviating post-operative symptoms.

Formosa Pharmaceuticals and AimMax Therapeutics collaborated to develop and obtain FDA approval for clobetasol propionate ophthalmic suspension. Eyenovia is poised to lead commercialization efforts in the US, facilitating access to this innovative treatment option for ophthalmologists and patients.

Clobetasol propionate ophthalmic suspension 0.05% is formulated using Formosa’s APNT nanoparticle platform, delivering a potent corticosteroid directly to the affected area. Notably, this is the first FDA-approved ophthalmic clobetasol propionate product and the first new steroid introduced to the ophthalmic market in over 15 years.

The approval was based on robust evidence from two randomized, double-masked phase 3 clinical trials involving over 750 subjects undergoing cataract surgery. The trials demonstrated that the suspension provided rapid and sustained clearance of inflammation, surpassing placebo with statistical and clinical superiority (P <.001).

With approximately seven million ocular surgeries performed annually in the US, there exists a substantial market for post-surgical ocular care products. Clobetasol propionate ophthalmic suspension presents a promising opportunity, with its favorable dosing regimen and efficacy profile positioning it to capture a significant share of the $1.3 billion annual market.

The approval of clobetasol propionate ophthalmic suspension represents a significant advancement in ocular care, offering clinicians and patients an effective solution for managing post-operative inflammation and pain. This milestone underscores the importance of innovation in addressing unmet needs in ophthalmology and improving patient outcomes.

Reference:

Inc. FP. Formosa Pharmaceuticals and Aimmax Therapeutics announce the NDA submission to the US FDA for APP13007 for the treatment of post-operative inflammation and pain following ocular surgery. PR Newswire: press release distribution, targeting, monitoring and marketing. May 5, 2023. Accessed March 4, 2024. https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-and-aimmax-therapeutics-announce-the-nda-submission-to-the-us-fda-for-app13007-for-the-treatment-of-post-operative-inflammation-and-pain-following-ocular-surgery-301815496.html.

Powered by WPeMatico

Yogurt consumption can reduce type 2 diabetes risk: FDA makes qualified health claim

USA: The U.S. Food and Drug Administration (FDA) announced in a letter of enforcement discretion that it will not object to using certain qualified health claims regarding yogurt consumption and reduced type 2 diabetes (T2D) risk.

The FDA, however, adds, “Yogurts that meet the FDA’s standard of identity will be allowed to carry qualified health claims provided that they are worded so as not to mislead consumers, and that other factors for the use of the claim are met.”

Following a review of the evidence, albeit limited evidence, the FDA said, “There is some credible evidence supporting a relationship between yogurt intake and reduced risk of type 2 diabetes.”

A health claim characterizes the relationship between a substance and a disease or health-related condition. A qualified health claim is supported by scientific evidence but does not meet the more rigorous “significant scientific agreement” standard required for an authorized health claim, the FDA stated. The agency has allowed such qualified health claims for dietary supplements since 2000 and food since 2002.

The FDA responded to a qualified health claim petition submitted on behalf of Danone North America requesting the agency to review the use of a qualified health claim concerning the relationship between yogurt consumption and reduced T2D risk for all types of yogurts that meet the FDA’s standard of identity.

The petition also noted that the evidence supports the health effects of yogurt as a food rather than related to any single nutrient or compound and thus is independent of sugar or fat content.

One study published in BMC Medicine in 2014, which supported this claim, showed that everyone serving yogurt per day was incrementally linked with a 17% lower risk for the development of type 2 diabetes (HR 0.83). The same study failed to find a significant association between total dairy consumption and type 2 diabetes risk.

The FDA considers two cups (3 servings) per week of yogurt to be the minimum amount for this qualified health claim.

The letter discusses the factors that the FDA intends to consider in the exercise of its enforcement discretion for the use of a qualified health claim on yogurt and the relationship between the consumption of yogurt and a reduced risk of type 2 diabetes.

The FDA intends to consider exercising its enforcement discretion for the following qualified health claims regarding the relationship between yogurt and reduced risk of type 2 diabetes:

  • “Eating yogurt regularly, at least 2 cups (3 servings) per week, may reduce the risk of type 2 diabetes. FDA has concluded that there is limited information supporting this claim.”
  • “Eating yogurt regularly, at least 2 cups (3 servings) per week, may reduce the risk of type 2 diabetes according to limited scientific evidence.”

Powered by WPeMatico

Include Robotic Surgery training in MCh Curriculum through NMC: Surgeons urge Govt

New Delhi: Highlighting the lack of proper training for robotic surgery in the country, the India Chapter of the Clinical Robotic Surgery Association (CRSA) recently submitted a representation urging the Director General of Health Services (DGHS) to include robotic surgery in the medical curriculum through the National Medical Commission (NMC).

Commenting on the matter, the President of CRSA, Vivek Bindal pointed out that there is currently no training curriculum for robotic surgery in India. He said, “We are looking to provide a guideline document to the Health Ministry to make robotic surgery a part of training for resident doctors and MCh (higher degree in surgical sciences) candidates.”

The popularity of Robotic Surgery is increasing in India because of its precision and minimal pain score when compared to Open Surgery and Laparoscopy.

Also Read: Doctors at Indraprastha Apollo Hospital perform robotic surgery to treat multiple uterine fibroids in 37 year old patient

Referring to this, CRSA President Bindal told Business Standard, “Robotic-assisted surgeries (RAS) have many benefits for patients such as early discharge, short hospital stay, fewer painkillers, fewer antibiotics, fewer complications, and less ICU stay.”

“RAS has come up in a big way in specialties such as gynaecology, oncology, and gastrointestinal surgeries. However, to make this technology available for all eligible patients, more surgeons need to get trained in robotic-assisted surgery,” he added.

Meanwhile, the senior consultant and Head of the Department (HoD) of Manipal Hospital, Dwarka, Randeep Wadhawan also highlighted the need for developing training pathways for such surgeries. 

He said that despite the increase in the number of robotic surgeries in India, the number of surgeons who can do such operations, compared to the number of population, is still much lesser.

“Currently, RAS training is given at certain centers of excellence, supported by private entities. There are 35 such centers as of today, which train surgeons in several specialties,” he added.

The National Board of Examinations in Medical Sciences (NBEMS) runs two-year fellowship programmes for minimum access surgeries to doctors after completion of their postgraduate degree course. Currently, robotic surgeons tend to opt for a fellowship course followed by clinical practice.

“During the advent of robotic surgery, this was acceptable. However, as robotic surgery continues to develop, it is imperative that robust training and credentialing systems are in place to ensure that patient safety and surgical outcomes are not compromised,” Wadhawan mentioned.

Also Read: Sharda Hospital organises India’s first International Robotic Workshop

Powered by WPeMatico

AI will always be a slave to us, we will remain the masters: AIIMS Director

Artificial Intelligence is always going to be artificial and the humans will remain the masters, Director AIIMS Delhi, Dr M Srinivas said on Thursday while outlining how the premier medical institute in the national capital is harnessing AI for the benefit of patients, including in cancer treatment.

Participating in ‘ANI Dialogues – Navigating India’s Health Sector’ here, Dr Srinivas said AI complements and supplements efforts and allows scalability and filtering at a faster pace.

For more information click on the link below:

Powered by WPeMatico

Former Union Health Minister Dr Harsh Vardhan quits politics

After a long political career of 30 years, the former Union Health Minister Dr. Harsh Vardhan has announced his decision to quit electoral politics.

In an X post, Dr Harsh Vardhan mentioned that he has promises to keep and announced his decision to go back to his ENT Clinic at Krishna Nagar. He further mentioned that he would continue to pursue his work against tobacco and substance abuse, against climate change as well as teaching simple and sustainable lifestyles.

For more information click on the link below:

Powered by WPeMatico

Health Bulletin 05/ March/ 2024

Here are the top health news for the day:

Dr Harsh Vardhan’s retirement from politics: Returning to his roots in ENT

After a long political career of 30 years, the former Union Health Minister Dr. Harsh Vardhan has announced his decision to quit electoral politics.

In an X post, Dr Harsh Vardhan mentioned that he has promises to keep and announced his decision to go back to his ENT Clinic at Krishna Nagar. He further mentioned that he would continue to pursue his work against tobacco and substance abuse, against climate change as well as teaching simple and sustainable lifestyles.

For more information click on the link below:


Delhi High Court halts pharma giant’s legal threats over ‘ELDER’ trademark dispute

In a significant legal development in New Delhi, the Delhi High Court issued an interim order restraining Mumbai-based Elder Projects from threatening Antex Pharma over the ‘ELDER’ and ‘ELDERVIT’ trademarks. Antex Pharma argued that their extensive use of these trademarks for pharmaceutical products has garnered significant goodwill, while Elder Projects allegedly made baseless legal threats to assert rights over them. The court’s decision reflects a cautious approach, balancing the protection of Antex Pharma from intimidation tactics with the recognition that ownership of the ‘ELDER’ trademark belongs to Elder Pharmaceuticals Ltd., as confirmed by a 2019 judgment. This ruling nullifies Elder Projects’ claims. The interim order not only provides temporary relief to Antex Pharma but also signals the court’s acknowledgment of the importance of fair competition and protecting established trademarks in the pharmaceutical industry. As the case progresses, it will have implications for trademark law and corporate practices in India’s pharmaceutical sector, showcasing the judiciary’s role in navigating trademark disputes.

AIIMS Director: “Artificial Intelligence will forever serve us; we retain control”
Artificial Intelligence is always going to be artificial and the humans will remain the masters, Director AIIMS Delhi, Dr M Srinivas said on Thursday while outlining how the premier medical institute in the national capital is harnessing AI for the benefit of patients, including in cancer treatment.

Participating in ‘ANI Dialogues – Navigating India’s Health Sector’ here, Dr Srinivas said AI complements and supplements efforts and allows scalability and filtering at a faster pace.

For more information click on the link below:


Lancet study exposes India’s dual nutritional crisis: From undernutrition to obesity
The recent Lancet study sheds light on India’s significant nutritional transition, revealing the dual challenges of undernutrition and obesity. Nutritionists attribute this “double whammy” to factors such as inadequate consumption of nutritious foods and the easy availability of cheap, unhealthy alternatives. Published by the NCD Risk Factor Collaboration (NCD-RisC) and the World Health Organization (WHO), the study highlighted concerning figures, with nearly 44 million women and 26 million men identified as obese in 2022, alongside approximately 12.5 million overweight children aged between five and 19.
Reference: NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. DOI:https://doi.org/10.1016/S0140-6736(23)02750-2

Powered by WPeMatico

NBE To hold Foreign Dental Screening Test 2023 For MDS Graduates On March 16, Check out all Exam Details here

New Delhi- The National Board of Examination in Medical Sciences (NBEMS) has announced the conduction of the Foreign Dental Screening Test 2023, FDST for MDS Degree and PG Diploma graduates. For this, NBE has also released an information bulletin detailing the scheme of examination, test day procedures in computer-based tests and other details.

NBE is conducting a Foreign Dental Screening Test (FDST) for Indian Nationals/OCIs possessing MDS Degree/PG Diploma Dental qualification awarded by Dental Institutions outside India on 16th March 2024 on a computer-based platform in Delhi.

IMPORTANT DATES

Issuance of Admit Cards

11th March 2024

Examination Date

16th March 2024

Declaration of Result

by 15th April 2024

SCHEME OF EXAMINATION

1 As per Principal Dental Council of India Screening Test Regulations, 2009, the exam consists of two question papers, comprising 100 and 150 multiple-choice, single-correct response questions in English language only.

2 The examination shall be a multiple-choice question delivered as a Computer Based Test.

3 FDST is divided into two question papers of 100 and 150 questions with time allocation of 120 minutes and 180 minutes respectively.

4 Allocation of time for the FDST (MDS Degree/PG Diploma) shall be as follows:

ACTIVITIES

PAPER-II

PAPER-II

Allow Candidates to enter the examination centre and Commence Registration

08:30 AM

12:30 PM

Entry closes at the Examination Center

10:00 AM

02:00 PM

Grant access for Candidate Login

10:15 AM

02:15 PM

Candidates log in to read instructions

10:20 AM

02:20 PM

Exam Start Time

10:30 AM

02:30 PM

Exam End Time

12:30 PM

05:30 PM

5 Negative Marking: There shall be no negative marking.

6 Each Question carries one mark.

7 There will be no grace marks. The candidate has to score 50% in each paper individually to qualify for appearing in the viva‑voce examination.

8 MDS/PG Diploma -Viva Voce Examination: 50 Marks. The candidate has to separately score 50% in the viva voce examination.

9 The standard of Foreign Dental Screening Test in respect of MDS Degree/PG Diploma holders would be at par with the standard prescribed for Indian Universities.

10 There shall be two examiners for Viva-Voce, out of whom, one internal from the examining university and one external from any other university which awards recognized Undergraduate and Postgraduate Dental qualifications.

11 There are no restrictions on the number of attempts that can be availed by a candidate.

OVERVIEW OF COMPUTER-BASED TEST

Reporting at the Test Centre on the Schedule Date and Time

                                 ⬇️

Security Check-in Process

                                 ⬇️

Registration for Test + Face ID/Biometric Capture

                                 ⬇️

Examination Begins

                                 ⬇️

Examination Ends

ADMIT CARDS

1 Candidates appearing for the Foreign Dental Screening Test 2023 can download the admit card from the NBEMS website.

2 Admit cards will be issued from 11th March 2024 onwards.

3 Candidates will be informed through SMS/Email alerts and website notices regarding the availability of the admit card on the NBEMS website. Admit card will not be sent to the candidates by Post/ Email.

4 Candidates are required to download their admit card from the NBEMS website and affix firmly their latest passport-size photograph in the space provided on the admit card.

TEST DAY PROCEDURES

NBEMS shall be conducting the Computer Based Test (CBT) in a safe and secure environment maintaining social distancing norms wherever needed. NBEMS reserves its right to review the test day processes of conduct of CBT in the wake of the changing scenario of the COVID-19 pandemic.

RESULT

1 Result – (Pass/Fail) for eligible candidates shall be displayed on the NBEMS website.

2 An applicant shall be declared as having passed only if he/she scores 50% in each paper individually to qualify for appearing in the viva-voce examination.

3 Viva-Voce examination consists of 50 marks. The candidate has to score 50% in the viva-voce examination i.e. 25 / 50.

4 The scheme regarding the delivery of an authenticated copy of the result shall be indicated on the website at the time of declaration of the result.

5 There will be no re-evaluation or rechecking or re-totaling. Requests for re-evaluation/re-totaling shall not be entertained.

6 The results for FDST 2023 – MDS Degree/PG Diploma are likely to be declared by 15th April 2024. Results can be seen on the NBE official website.

For any queries, candidates may contact NBEMS Candidate Care Support or write to NBEMS on its communication web portal.

The National Examination Board is an autonomous organisation of the Ministry of Health and Family Welfare, Government of India.

To view the official notice, click the link below

Powered by WPeMatico

Special insecticide paint may help curb Zika and dengue fever outbreaks

Malaria and other illnesses caused by parasites, viruses, and bacteria transmitted by organisms that spread infectious pathogens account for more than 17% of all infectious diseases worldwide. These vector-borne diseases, typically transmitted by insects like mosquitoes, flies, and ticks, disproportionally affect the poorest populations in tropical and subtropical regions.

Powered by WPeMatico

The effects of ‘blue light’ on human health are still unclear, says panel

For years, scientists have expressed concern about potential adverse health effects of excessive exposure to short wavelength light (SWL), which includes the “blue light” from smartphones, laptops, and tablets. However, the International Commission on Non-Ionizing Radiation Protection (ICNIRP) has identified a lack of consensus among public health officials about whether SWL from artificial sources disrupts circadian rhythm, and if so, whether SWL-disrupted circadian rhythm is associated with adverse health outcomes.

Powered by WPeMatico